Estradiol and Cardiovascular Disease
The Evidence Supports Optimizing Estradiol
Early in Menopause
Worldlink Medical Journal Club Practitioners Discuss
the ELITE Study
Presented by Ilona Bleaman, PA-C
ELITE Trial conducted from 2005-2008 in 643 post-menopausal women, evaluating the timing of HRT in relation to menopause for preventing atherosclerosis
- participants were given
- vaginal progesterone plus either
- 1MG estradiol
- placebo
- vaginal progesterone plus either
- evaluated using
- carotid intima media thickness (CIMT)
- coronary calcium scores (CT)
- carotid intima media thickness (CIMT)
- early HRT is better than late for CIMT
- null results for CT calcium scores
- timing of HRT since menopause defined as <6 years and >/= 10 years
- Journal Club* panel conclusions:
- oral estradiol is safe
- support for the "timing hypothesis" - estradiol given early in menopause is cardioprotective
Membership with Worldlink Medical offers exclusive access to tools that help you educate your patients more effectively.
Monthly Journal Clubs*, like the one this excerpt was taken from, give you in-depth insight into important studies about optimal hormones from experienced Worldlink practitioners.
Members dive deep into the evidence for optimizing bioidentical hormones in Journal Clubs and Webinars and get access to full text articles through EBSCO Research Library. Click the button to learn more.